PatientsVille.com Logo


Antabuse Medical Research Studies

Up-to-date List of Antabuse Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Antabuse Medical Research Studies

Rank Status Study
1 Unknown  Antabuse in Severe Alcoholism: an Open Controlled Study
Condition: Alcoholism
Intervention: Drug: Antabuse (disulfiram)
Outcome Measure: The number of patients in each group who have not been drinking alcohol after 6 months of treatment.
2 Recruiting Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study
Conditions: HIV;   Human Immunodeficiency Virus
Intervention: Drug: Disulfiram
Outcome Measures: Cell associated HIV RNA;   Plasma HIV RNA;   Proviral HIV DNA
3 Recruiting Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide
Condition: Glioblastoma
Interventions: Drug: Temozolomide;   Drug: Disulfiram
Outcome Measures: Pharmacological effect of disulfiram in GBM patients;   Local tumor control probabilities;   Time to tumor progression
4 Not yet recruiting Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform
Condition: Glioblastoma Multiforme
Interventions: Drug: Temozolomide;   Drug: Disulfiram;   Drug: Copper
Outcome Measures: Progression-free survival;   Overall survival
5 Not yet recruiting A PET Exploration of the Mechanism of Action of Dopamine Beta-hydroxylase Inhibition in Cocaine Addicts
Condition: Cocaine Dependence
Interventions: Drug: Disulfiram;   Drug: Placebo
Outcome Measures: Variations in linkage rates of 11Craclopride in the nucleus accumbens between baseline TEP measurement and TEP measurement following administration of 20 mg of methylphenidate.;   DBH activity as measured directly, and indirectly by the DHPG / DOPAC report.;   Measurement of craving in cocaine by a simple Likert scale.;   Measure of aversion to cocaine by a simple Likert scale.
6 Recruiting Trial of Amitriptyline for Chronic Oral Food Refusal in Children 9 Months to 8 Years of Age
Condition: Chronic Oral Food Refusal
Interventions: Drug: Amitriptyline 1 mg/kg;   Drug: Placebo
Outcome Measures: To assess the efficacy of amitriptyline in a 24-week outpatient multi-disciplinary protocol for transitioning children from tube to oral feeding;   To assess the role of pain in the efficacy of amitriptyline in the 24-week outpatient multidisciplinary protocol.
7 Unknown  Data Registry of Intensive Care Unit (ICU) Siamitra and Intensive Care Unit (ICU) Salad-Samung
Condition: Complication
Outcome Measures: Incidence of ICU refusal;   ICU complication, resource utilization and adverse events/ICU readmission within 72 hours after discharging from ICU
8 Recruiting An Interactive Game for HIV Prevention in Early Adolescents
Conditions: HIV;   Risk Reduction
Interventions: Behavioral: Experimental Video Game;   Behavioral: Off the Shelf Video Game
Outcome Measures: Delay in the initiation of sexual activity;   Knowledge about HIV/AIDS risk behaviors and transmission;   Level of social competency in using negotiating and refusal skills in the virtual environment;   Level of self-efficacy regarding negotiation around initiation of sexual activity;   Drug and alcohol use behaviors;   Level of self-efficacy in negotiating situations involving offers of drugs and alcohol;   Overall risk-taking behaviors
9 Recruiting Technology-supported Behavioral Feeding Intervention
Condition: Feeding and Eating Disorders of Childhood
Intervention: Behavioral: Technology Supported Manual
Outcome Measures: Mealtime Behaviors;   Parenting Stress Index- Short Form
10 Unknown  Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study (SAFADIE)
Condition: Alcohol Dependence
Interventions: Drug: Acamprosate (Campral);   Drug: Acamprosate
Outcome Measures: The primary outcome will be safety.;   Changes in the quantity of alcohol consumed as determined by Time Line Follow Back assessment by patient and parallel historian will be determined.
11 Recruiting Geriatric Group Psychoeducational Intervention for Elderly Patients With Cancer
Conditions: Breast Cancer;   Prostate Cancer;   Lung Cancer;   Lymphoma Cancer;   Gynecological Cancers
Interventions: Behavioral: group intervention and questionnaires;   Behavioral: individual phone intervention and questionnaires
Outcome Measures: To test the feasibility, tolerability and acceptability of a Geriatric Specific Psychoeducational Intervention (GSPI) by examining the rates of eligibility, acceptance, and adherence.;   To examine the impact of these GSPI in both formats on depressive symptoms, anxiety, demoralization, coping, loneliness and isolation, and spirituality compared to the control group.
12 Recruiting Efficacy And Safety Of Xeliri + Avastin Followed By Xelox + Avastin Or Reverse Sequence In Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Capecitabine;   Drug: Bevacizumab;   Drug: Oxaliplatin;   Drug: Irinotecan
Outcome Measures: Efficacy Duration of disease control by tumor assessment (CT/MRI/clinical examination);   first line progression free survival (PFS);   second line PFS;   overall response rate;   time to response;   duration of response;   overall survival of XELIRI plus bevacizumab and XELOX plus bevacizumab;   tumour assessments (based on RECIST criteria)
13 Recruiting Internet-Based Sexual Health Education for Middle School Native American Youth
Conditions: Sexually Transmitted Diseases;   Pregnancy;   HIV Infections
Interventions: Behavioral: HIV, STI and Pregnancy Prevention Curriculum;   Behavioral: Control Curricula
Outcome Measures: Delay onset of sexual activity;   Reduce alcohol/drug use;   Reduce instances of sexual activity;   Decrease the number of sexual partners;   Condom use during sexual activity;   Contraceptive use while sexually active;   Prevalence of sexually transmitted infections;   Increase sexual knowledge;   Changes in sexual beliefs;   Changes in attitudes toward sexual activity;   Changes in perception of sexual beliefs among peers;   Increased self-efficacy for refusal skills;   Increased self-efficacy for condom use;   Increased avoidance of risky situations;   Changes in perceived norms about sexual activity;   Changes in reasons for or against having sex;   Changes in intentions to have/abstain from sex
14 Recruiting Individual vs. Group Community Reinforcement Training to Help Parents of Substance-using Treatment-refusing Youth
Conditions: Substance Use Disorders;   Treatment Refusal
Interventions: Behavioral: Group Community Reinforcement Training for Parents;   Behavioral: Individual Community Reinforcement Training for Parents
Outcome Measures: Adolescent treatment engagement;   Timeline Followback (TLFB) interview
15 Recruiting A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma
Condition: Glioblastoma Multiforme
Interventions: Drug: axitinib;   Drug: Axitinib plus Lomustine
Outcome Measure: anti-tumor effect of axitinib as a single therapeutic agent and in combination with Lomustine
16 Recruiting Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Interventions: Drug: AFLIBERCEPT;   Drug: Irinotecan;   Drug: 5-Fluorouracil;   Drug: Folinic Acid
Outcome Measures: Progression-Free Survival (PFS) rate at 1 year;   Evaluation of Objective Response Rate (ORR) defined as the proportion of patients with complete response (CR) or partial response (PR) among all patients, as assessed according to Response Evaluation Criteria for Solid Tumors (RECIST) v1.1;   Evaluation of Overall Survival (OS);   Evaluation of Progression-Free Survival (PFS);   Number of participants with Serious and Non-Serious Adverse Events graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0;   Tumor tissue mRNA levels of VEGFA-121, VEGFA121b, VEGF-B, PlGF, VEGF-C, Semaphorins, HIF1, VEGFR1, VEGFR2, Neuropilins 1,2, Thrombospondin, Angiopoietins 1,2. Predictive significance for response rate, PFS, OS.;   Steady-state concentration of free Aflibercept and VEGF-bound Aflibercept in plasma. Predictive significance for response rate, PFS, OS.;   Enzyme-linked immunosorbent assay (ELISA) plasma concentrations of VEGFA, soluble VEGFR1, soluble VEGFR2, VEGF-B, PlGF, basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF). Predictive significance for response rate, PFS, OS.
17 Recruiting Endoscopic Ultrasound-guided Fine Needle Biopsy With 25-gauge Biopsy Needles for Solid Pancreatic Masses
Condition: Solid Pancreatic Masses
Intervention: Device: EUS-FNB with 25-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)
Outcome Measures: accessing the rate for procurement of the histologic core;   the percentage of cases in which pathologists classified the sample quality as optimal for histological evaluation of 25-gauge biopsy needle
18 Unknown  A Novel Pharmacotherapy for Alcoholism and Alcohol Liver Disease
Conditions: Alcoholism,;   Alcoholic Liver Disease
Interventions: Drug: Metadoxine;   Drug: Placebo
Outcome Measures: Percent Days Abstinent (PDA);   AST/ALT ratio;   Follow-up PDA;   Liver Tests;   Quality of Life;   Alcohol Craving;   Adverse Events
19 Recruiting A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer
Condition: Carcinoma, Hepatocellular
Interventions: Drug: PF-03446962;   Other: Best Supportive Care;   Other: Placebo
Outcome Measures: Overall Survival (OS);   Time to Tumor Progression (TTP);   Progression-Free Survival (PFS);   Objective Response Rate;   Duration of Response (DR);   Disease Control Rate (DCR) at 16 weeks;   Change From Baseline in Functional Assessment of Cancer Therapy-Hepatobiliary questionnaire (FACT-Hep);   Maximum serum concentration (Cmax);   Trough serum concentration of PF-03446962 (Ctrough;   Observed serum concentration of circulating protein;   Ratio to baseline of serum circulating protein concentration;   Ratio to baseline of tumor mRNA transcript
20 Recruiting Modified Folinic Acid-Fluorouracil-Oxaliplatin Regimen + Capecitabine for Elderly With Metastatic Gastric Cancer
Condition: Metastatic Gastric Cancer
Interventions: Drug: folinic acid+fluorouracil+oxaliplatin;   Drug: Capecitabine
Outcome Measures: progression-free survival;   PFS on capecitabine maintenance;   overall survival;   number of patients with adverse events;   tolerability;   time to treatment failure;   Quality of life

These studies may lead to new treatments and are adding insight into Antabuse etiology and treatment.

A major focus of Antabuse research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Antabuse